WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)
Clinical trial NCT01266083 · COMPLETED
Trial details
- NCT number
- NCT01266083
- Sponsor
- Sellas Life Sciences Group
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2011-01-14
- Primary completion
- 2016-09-30
- Enrollment
- 22
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.